Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
Gilbert A. Fuller, a director of USANA Health Sciences Inc (USNA), reported a sale of 1,058 shares of common stock on 08/07/2025 at approximately $29.1014 per share. The Form 4 lists the transaction as a sale and shows 0 shares beneficially owned by Fuller following the reported transaction, with ownership held directly. The filing discloses the required Section 16 details for the transaction.
USANA Health Sciences, Inc. (USNA) — Quarterly report (10-Q) for period ended June 28, 2025.
Key financials: Net sales were $235.8M for Q2 2025, up 10.8% y/y; six‑month net sales were $485.4M. Net earnings attributable to USANA were $9.7M for Q2 (Q2 2024: $10.4M) and $19.1M for six months (prior: $27.0M). Diluted EPS was $0.52 for the quarter and $1.01 for six months.
Material events and balance sheet highlights: the company completed a controlling acquisition of Hiya on December 23, 2024 for a final purchase price of $206,074, recognizing $127.3M of goodwill and $124.2M of intangibles (acquired). Cash and cash equivalents were $151.3M as of June 28, 2025 ($154.1M total cash, cash equivalents and restricted cash). Inventories increased to $83.3M. During the six months the company repurchased and retired 927 shares for $27.7M. A redeemable noncontrolling interest in Hiya totaled $54.5M. The Credit Facility provides up to $75.0M revolver capacity; outstanding balance was $0 at June 28, 2025.
USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.
- Transaction date: 30 Jul 2025
- Shares sold: 3,515 common shares
- Sale price: $30.26 per share (approx. $106 k total proceeds)
- Shares owned after sale: 9,260 (direct)
No derivative securities were reported. The filing was signed on 31 Jul 2025.
USANA Health Sciences (USNA) filed a Form 144 indicating an insider’s intent to sell 3,515 common shares through Morgan Stanley Smith Barney on or after 30 Jul 2025. The shares have an aggregate market value of $106,364, based on the filing date, and represent roughly 0.02 % of the company’s 18.6 million shares outstanding.
The stock being sold was acquired as restricted-stock awards: 1,138 shares granted on 4 Feb 2022 and 2,377 shares granted on 6 Feb 2025. No prior insider sales were reported in the past three months, and the filer affirms possession of no undisclosed material adverse information.
The transaction is modest relative to USNA’s float and appears to be a routine liquidity event rather than a signal of fundamental change. Nevertheless, investors often monitor Form 144 filings for potential sentiment shifts among insiders.
USANA Health Sciences (USNA) – Form 4 filing
On 24-Jul-2025, CEO & President Jim Brown converted 2,190 previously granted restricted stock units (code “M”) into an equal number of common shares. To satisfy withholding taxes, 972 of those shares were automatically surrendered to the issuer at $32.09 per share (code “F”). The net effect is an increase of 1,218 directly held shares, bringing Brown’s direct common-stock ownership to 16,934. He also retains 160,878 unvested/derivative RSUs that will convert into common shares as they vest. No open-market purchases or sales occurred; all transactions were internal equity-compensation settlements. The filing does not disclose any broader corporate developments.
USANA Health Sciences (USNA) Form 4 – Director Ding Xia reported routine equity transactions dated 24 Jul 2025.
- Exercise of RSUs (Code M): 1,058 restricted stock units converted 1:1 into common shares, increasing direct holdings.
- Tax‐withholding sale (Code F): 265 shares were surrendered at $32.09 to satisfy withholding obligations.
- Post-transaction ownership: 5,337 common shares held directly and 3,172 unvested RSUs remain outstanding. RSUs vest 25 % on four quarterly dates between 24 Jul 2025 and 23 Apr 2026.
No purchase or sale of shares for investment purposes occurred; the net change (+793 shares) stems from normal equity compensation. No other directors or officers are listed, and there is no indication of material information affecting USNA’s operations or outlook.
USANA Health Sciences (USNA) Form 4: Director John Turman Fleming reported the automatic conversion of 1,058 Restricted Stock Units (RSUs) into an equal number of common shares on 24 Jul 2025 (transaction code M – derivative conversion). No cash price was paid at conversion.
Post-transaction holdings:
- Common stock held directly: 5,258 shares (up from 4,200).
- Unvested RSUs remaining: 3,172 units.
The RSU award vests in four equal tranches of 25% each on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. Fleming’s filing reflects the first vesting event. There was no open-market buying or selling; the transaction simply moves shares from derivative to common ownership, marginally increasing the director’s freely tradable stake.
Given the modest size relative to USNA’s ~19 million outstanding shares, the event is immaterial to corporate finances. It does, however, signal continued equity alignment between the director and shareholders.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
